Ask AI
ProCE Banner Activity

CE / CME

Pain Points: Leveling Up Strategies for Safe Opioid Use and Pain Management

Patient Simulation

This interactive patient simulation series provides REMS-compliant CME/CE/CPE credits where learners gain a deep understanding of safe opioid practices and current guidelines. HCPs level up their knowledge in pain management, safe opioid prescribing, appropriate referral practices, patient education, and opioid use disorder to provide the highest level of personalized care to their patients, ensuring responsible opioid use in healthcare practices.

 

Instructions:

  • Participants must review all activity information, including the pre-test, learning objectives, faculty disclosure information, simulation scenario(s) and post-activity evaluation.
  • To view the first simulation scenario, launch the simulation from the link provided using a PC, Mac, Tablet, or Phone with a 4G or higher internet connection.
  • The simulation will track your progress until all scenario objectives are complete.
  • Exit the simulation at any time, and your progress will be saved so you can return to finish at a later time.

Nurse Practitioners/Nurses: 2.00 Nursing contact hours, including 2.00 hours of pharmacotherapy credit

Physician Assistants/Physician Associates: 2.00 AAPA Category 1 CME credits

Pharmacists: 2.00 contact hours (0.2 CEUs)

Physicians: maximum of 2.00 AMA PRA Category 1 Credits

Released: December 22, 2025

Expiration: October 31, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

This activity is supported by an independent educational grant from the Opioid Analgesic REMS Program Companies.

Please see https://www.opioidanalgesicrems.com/Resources/Docs/List_of_RPC_Companies.pdf for a listing of REMS Program Companies. This activity is intended to be fully compliant with the Opioid Analgesic REMS education requirements issued by the U.S. Food and Drug Administration (FDA).

Opioid Analgesic REMS Program Companies

Target Audience

The Opioid REMS interactive program is intended to reach interprofessional and multidisciplinary healthcare teams, including physicians, advanced practice nurses, physician associates, pharmacists, and nurses. Specialty areas include but are not limited to psychiatry, neurology, family medicine, internal medicine, pain management, physiatry, and surgery. This includes HCPs who are involved with direct patient care, including HCPs registered with the DEA and eligible to prescribe all opioid analgesics, as well as nonprescribers involved in the care of patients receiving opioid analgesic therapy, nonpharmacologic therapies, and nonopioid medication therapies.

Program Learning Goal

Educate HCPs on safe prescribing practices for opioid medications, aiming to reduce the risk of addiction, misuse, overdose, and death by providing information on appropriate patient assessment, pain management strategies, and monitoring practices when prescribing opioids for pain treatment.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Differentiate the types of pain, including definitions, etiology, mechanisms, and risk factors

  • Identify risk factors for nonmedical use and opioid use disorder as part of a thorough assessment of pain and refer to addiction medicine specialists when appropriate

  • Develop individualized pain management plans considering all therapeutic options, including nonpharmacologic interventions, nonopioid medications, and opioid analgesics

  • Counsel patients and caregivers on the safe use, storage, and disposal of opioid analgesics and the role of reversal agents

  • Monitor patients receiving opioid therapy, including reviewing medication adherence, need for referral to pain specialist, potential for nonmedical use, and situations when it is appropriate to taper or discontinue opioid therapy

  •  Construct a systematic approach to screening for and appropriately managing patients with opioid use disorder

Disclosure

Decera Clinical Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to Decera Clinical Education policy. Decera Clinical Education is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Michael Sprintz, DO, DFASAM: consultant/advisor/speaker: Advanced Genomics Laboratory, Patch Technologies, Spark Biomedical, Tafalgie Therapeutics; individual publicly traded stock/stock options: Bridge Therapeutics.

Amanda Zimmerman, PA-C: consultant/advisor/speaker: Averitas.

The planners and content peer reviewers from Decera Clinical Education do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 2 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 22, 2025, through October 31, 2026:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC dba Decera Clinical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Clinical Care Options, LLC dba Decera Clinical Education designates this enduring material for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 2 contact hours, including 2 hour of pharmacotherapy credits.

Continuing Pharmacy Education

Clinical Care Options, LLC dba Decera Clinical Education designates this continuing education activity for 2 contact hours (0.20 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number: JA4008176-0000-25-492-H08-P

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Associate Continuing Medical Education

Clinical Care Options, LLC dba Decera Clinical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 2 AAPA Category 1 CME credits. Approval is valid until October 31, 2026. PAs should only claim credit commensurate with the extent of their participation.

IPCE Credit Designation

A logo for a credit companyAI-generated content may be incorrect.

This activity was planned by and for the healthcare team, and learners will receive 2 Interprofessional Continuing Education (IPCE) credits for learning and change.

A logo for a companyDescription automatically generated

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.

Additional Information

Copyright Statement
This CME simulation activity is licensed to Clinical Care Options, LLC dba Decera Clinical Education. Copyright © 2025 Syandus Inc and Decera Clinical Education. All rights reserved. No part of this simulation activity may be reproduced without written permission from Decera Clinical Education and Syandus Inc.